Premarket Biotech Digest – $BIIB receives price upgrade, $ABT receives conditional approval, $OPK reports test updates

ImmunoGen Inc. ($IMGN) stock scaled 29% to close at $2.04 in its previous trading session. The stock movement corresponded to the news of its drug candidate mirvetuximab soravtansine showing encouraging results in responding to and improving progression-free survival (PFS) in folate receptor alpha positive [...]

By |January 2nd, 2017|Digest|0 Comments

Premarket Biotech Digest – $ALR files appeal, $ELGX restarts shipment, $ICPT talks with $NVS

  • Alere ($ALR) announced filing an appeal against revocation of Medicare billing privileges for its Arriva Medical Unit. The appeal has been made to an administrative law judge at the Centers for Medicare and Medicaid Services. The decision is expected within three months. [...]

By |December 30th, 2016|Digest|0 Comments

Premarket Biotech Digest – $ABC settles lawsuit, $SNY sues $NVO, $MYL launches generic Zovia

  • AmerisourceBergen ($ABC) and Cardinal Health ($CAH) announced settling a lawsuit related to painkiller shipments. The lawsuit alleged that the distributors fed an ongoing opioid epidemic with excessive shipments over the years. • Sanofi ($SNY) announced suing Novo Nordisk ($NVO) stating that the [...]

By |December 29th, 2016|Digest|0 Comments

Premarket Biotech Digest – $PTLA gets priority review, $ANTH misses endpoint, $ELGX holds shipping

• Portola Pharmaceuticals’ ($PTLA) new drug application has been accepted by the FDA for priority review. The application pertains to its oral, once-daily Factor Xa inhibitor anticoagulant, betrixaban. The company is looking to get the drug approved forextended-duration prophylaxis of venous thromboembolism (VTE) in [...]

By |December 28th, 2016|Digest|0 Comments

Premarket Biotech Digest – $SCMP gets rating upgrade, $IONS receives approval, $CAH settles suit

  • Cardinal Health ($CAH) announced settling the outstanding civil penalty portion of its 2012 administrative settlement with the U.S. Drug Enforcement Agency (DEA). The company agreed to pay $44 million. • Bloomberg reported that NewLink Genetics’ ($NLNK) experimental Ebola vaccine, rVSV-ZEBOV, showed promising [...]

By |December 27th, 2016|Digest|0 Comments

Premarket Biotech Digest – $MYGN slumps, $AVGR receives approval, $MRUS receives rating upgrade

Neothetics ($NEOT) shot up in its previous trading session and ended 19.79% higher at $1.15. The main impetus for the stock came from the news that it has started a Phase 2 clinical trial, LIPO-202-CL-31, evaluating lead product candidate LIPO-202 for the reduction of [...]

By |December 26th, 2016|Digest|0 Comments

Premarket Biotech Digest – $PFE acquires new business, $TEVA pays penalty, $INO reports +VE results

Tokai Pharmaceuticals ($TKAI) stock shot up in Thursday trading session as the company announced its agreement with Otic Pharma Ltd., a privately-held, clinical-stage pharmaceutical company. The collaboration pertains to a definitive share purchase program which will make Otic Pharma shareholders the majority owners of [...]

By |December 23rd, 2016|Digest|0 Comments

Premarket Biotech Digest – $MRUS inks new deal, $NEOS files NDA, $NEOG reports Q2 results

Gainers (% price change) Last Trade Change Mkt Cap Clovis Oncology Inc CLVS (NASDAQ) 46.20 +3.68 (8.65%) 1.87B China Cord Blood Corp CO (NYSE) 5.31 +0.40 (8.15%) 430.84M Derma Sciences Inc DSCI (NASDAQ) 5.60 +0.35 (6.67%) 169.62M PDL BioPharma Inc PDLI (NASDAQ) 2.08 +0.10 (5.05%) 340.88M Oclaro, Inc. OCLR (NASDAQ) [...]

By |December 22nd, 2016|Digest|0 Comments

Premarket Biotech Digest – $BMY secures global rights, $PARN to delist, $TNXP receives Hold rating

Bristol-Myers Squibb ($BMY) extended its portfolio by securing exclusive worldwide rights to PsiOxus Therapeutics' NG-348, a preclinical stage "armed" oncolytic virus which may potentially be used to treat solid tumors. The agreement calls for $50M upfront payment to PsiOxus. The company is also entitled [...]

By |December 21st, 2016|Digest|0 Comments

Premarket Biotech Digest –$JUNO prevails, $REGN receives rating upgrade, $PTHN reports Q4 results

Portola Pharmaceuticals ($PTLA) announced that it has entered into an agreement with Pfizer ($PFE) and Bristol-Myers Squibb ($BMY) for an unsecured $50 million. The funds will be used for carrying out the development actions for Factor Xa antidote AndexXa (andexanet alfa). Each company will [...]

By |December 20th, 2016|Digest|0 Comments

Premarket Biotech Digest – $AGIO halts anemia study, $MRK wins patent case, $NEO gets overweight rating

Evoke Pharma ($EVOK) reported that the FDA has taken a positive stance regarding its marketing application for Gimoti. The medicine is a nasal delivery formulation of metoclopramide for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in adult women. The FDA [...]

By |December 19th, 2016|Digest|0 Comments

Premarket Biotech Digest – $BAX buys Claris Unit, $SNY negotiates with Actelion, $ATHN provides guidance

Baxter International Inc. ($BAX) announced acquisition of Claris Injectables Unit. The deal is reported to be worth $625 million. Baxter expects the new collaboration to help it develop seven to nine new generic injectable medicines a year. The companies expect to seal the deal [...]

By |December 16th, 2016|Digest|0 Comments

Premarket Biotech Digest – $BCLI reports +VE results, $CTMX receives FDA approval, $BRKR receives rating downgrade

Brainstorm Cell Therapeutics ($BCLI) reported positive results from a 48-subject Phase 2 study assessing NurOwn in patients with amyotrophic lateral sclerosis (ALS). The stock reacted positively to the news and touched $2.88 in Wednesday trading session. The stock closed at $2.62, up 21.86%. The [...]

By |December 15th, 2016|Digest|0 Comments

Premarket Biotech Digest – $JNJ pulls from Actelion bid, $BMY restructures R&D, $LLY receives FDA approval

Vericel ($VCEL) stock shot up in pre-market trading hours and gained over 53%. The stock had closed the previous trading session with 1.89% decline at $2.60. The massive jump in the scrip price is in response to the company’s announcement regarding the receipt of [...]

By |December 14th, 2016|Digest|0 Comments

Premarket Biotech Digest –$AKRX jumps, $NVCR reports +VE results, $PPHM reports quarterly results

Akorn Inc. ($AKRX) stock jumped over 8% in the previous trading session, ultimately closing at $20.21, showing 8.66% gain. The stock reacted to the news of the USFDA conducting a reinspection of the company’s facility in Decatur. The agency had conducted another survey earlier [...]

By |December 13th, 2016|Digest|0 Comments

Premarket Biotech Digest – $LLY signs deal, $SGMO stock jumps, $MD gets neutral rating

Sangamo BioSciences Inc. ($SGMO) stock snapped its negative streak as it jumped to $3.35 in its Friday trading session. The stock eventually closed at $3.20, 18.52% higher. The company presented preclinical and manufacturing data that support SB-525, its gene therapy program for hemophilia A, [...]

By |December 12th, 2016|Digest|0 Comments

Premarket Biotech Digest – $EW announces 2017 targets, $HZNP announces -VE results, $ENDP signs new deal

Edward Lifesciences Corp ($EW) announced its financial benchmarks for 2017. The stock responded by jumping to $91.34 in its previous trading session. It finally closed at $89.30, up 6.65% from its previous close. However, the company also reported that its fourth quarter sale figure [...]

By |December 9th, 2016|Digest|0 Comments

Premarket Biotech Digest – $ABMD received FDA approval, $BIOVF signs agreement, $BLUE receives Buy rating

AcelRx Pharmaceuticals Inc. ($ACRX) stock jumped to $3.10 in its previous trading session, before closing at $3.05, up 5.17% from its last close. The company stock lost 38% of its value in the last one year. However, it has shown remarkable recovery in the [...]

By |December 8th, 2016|Digest|0 Comments

Premarket Biotech Digest – $IMMU shows +VE results, $JUNO stock downgraded, $APDN reports loss

Immunomedics Inc. (NASDAQ:IMMU) stock jumped to $3.79 during its previous trading session, before closing at $3.61, up 10% from its last close. The stock reacted to positive information about its drug candidate IMMU-140. The company reported that the investigational product from its antibody-drug conjugate [...]

By |December 7th, 2016|Digest|0 Comments

Premarket Biotech Digest – $ABBV announces new agreement, $BLCM reports +VE results, $NVLN signs licensing deal

Bioline RX Ltd ($BLRX) stock jumped 5.10% in its previous trading session to close at $1.03. The stock has gained 3% in the past six months. The company announced the results of a Phase 2a clinical trial for its lead product candidate BL-8040 The [...]

By |December 6th, 2016|Digest|0 Comments
s2Member®